- Home
- IPSC vs DHAI Comparison
IPSC vs DHAI Comparison
Compare IPSC & DHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- DHAI
- Stock Information
- Founded
- IPSC 2019
- DHAI 2007
- Country
- IPSC United States
- DHAI United States
- Employees
- IPSC N/A
- DHAI N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- DHAI
- Sector
- IPSC Health Care
- DHAI
- Exchange
- IPSC Nasdaq
- DHAI NYSE
- Market Cap
- IPSC 58.1M
- DHAI 49.1M
- IPO Year
- IPSC 2021
- DHAI N/A
- Fundamental
- Price
- IPSC $0.54
- DHAI $0.18
- Analyst Decision
- IPSC Strong Buy
- DHAI
- Analyst Count
- IPSC 5
- DHAI 0
- Target Price
- IPSC $3.67
- DHAI N/A
- AVG Volume (30 Days)
- IPSC 735.0K
- DHAI 1.8M
- Earning Date
- IPSC 05-20-2025
- DHAI 02-14-2025
- Dividend Yield
- IPSC N/A
- DHAI N/A
- EPS Growth
- IPSC N/A
- DHAI N/A
- EPS
- IPSC N/A
- DHAI N/A
- Revenue
- IPSC $6,589,000.00
- DHAI $69,573,000.00
- Revenue This Year
- IPSC $833.10
- DHAI N/A
- Revenue Next Year
- IPSC N/A
- DHAI N/A
- P/E Ratio
- IPSC N/A
- DHAI N/A
- Revenue Growth
- IPSC 194.81
- DHAI 5.40
- 52 Week Low
- IPSC $0.34
- DHAI $0.12
- 52 Week High
- IPSC $3.47
- DHAI $3.67
- Technical
- Relative Strength Index (RSI)
- IPSC 51.91
- DHAI 42.74
- Support Level
- IPSC $0.52
- DHAI $0.16
- Resistance Level
- IPSC $0.57
- DHAI $0.20
- Average True Range (ATR)
- IPSC 0.03
- DHAI 0.03
- MACD
- IPSC 0.00
- DHAI 0.01
- Stochastic Oscillator
- IPSC 58.75
- DHAI 27.88
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.